The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 548-553

  Salar, Antonio ^a   Haioun, Corinne ^b   Rossi, Francesca G ^c   Duehrsen, Ulrich ^d   Pettengell, Ruth ^e   Johnsen, Hans E ^f   Jaeger, Ulrich ^g   Verhoef, Gregor ^h   Schwenkglenks, Matthias ⁱ   Bacon, Pamela ^j   Bendall, Kate ^k   Lugtenburg, Pieternella J ^l  

^a HOSPITAL DEL MAR   (Spain)

^b HENRI MONDOR HOSPITAL   (France)

^c IRCCS   (Italy)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ UNIVERSITY OF BASEL   (Switzerland)

^j AMGEN INC   (United States)

^k Biostatistics   (United Kingdom)

^l ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Diffuse large B cell lymphoma; Febrile neutropenia; Granulocyte colony stimulating factor; R CHOP 21; Relative dose intensity; Risk assessment

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; HEMOGLOBIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL STATUS; HIGH RISK PATIENT; HUMAN; LARGE CELL LYMPHOMA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NEEDS ASSESSMENT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SENESCENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; PREDNISONE; RISK ASSESSMENT; RISK FACTORS; VINCRISTINE;

EID: 84858748086     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.02.002     Document Type: Article

References (27)

1. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
2. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
3. Pettengell R., Schwenkglenks M., Leonard R., Bosly A., Paridaens R., Constenla M., et al. Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU). Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008, 16:1299-1309.
4. Buske C., Hoster E., Dreyling M., Eimermacher H., Wandt H., Metzner B., et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009, 23:153-161.
5. Balducci L., Al-Halawani H., Charu V., Tam J., Shahin S., Dreiling L., et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007, 12:1416-1424.
6. Osby E., Hagberg H., Kvaloy S., Teerenhovi L., Anderson H., Cavallin-Stahl E., et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003, 101:3840-3848.
7. Mabthera(R) Summary of product characteristics. Roche Products Limited. Available from: [accessed 26.03.10]; 2010. http://emc.medicines.org.uk/medicine/2570.
8. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-2266.
9. Link B.K., Budd G.T., Scott S., Dickman E., Paul D., Lawless G., et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 2001, 92:1354-1367.
10. Pettengell R., Schwenkglenks M., Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 2008, 87:429-430.
11. Bosly A., Bron D., Van Hoof A., De Bock R., Berneman Z., Ferrant A., et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008, 87:277-283.
12. Green M.D., Koelbl H., Baselga J., Galid A., Guillem V., Gascon P., et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003, 14:29-35.
13. Aapro M.S., Cameron D.A., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006, 42:2433-2453.
14. Aapro M.S., Bohlius J., Cameron D.A., Dal Lago L., Donnelly J.P., Kearney N., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2010, 47:8-32.
15. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
16. Case D.C., Desch C.E., Kalman L.A., Vongkovit P., Mena R.R., Fridman M., et al. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first cycle filgrastim for elderly patients. Clin Lymphoma Myeloma 2007, 7:354-360.
17. Crawford J., Dale D.C., Kuderer N.M., Culakova E., Poniewierski M.S., Wolff D., et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Comprehensive Cancer Network 2008, 6:109-118.
18. Lyman G.H., Morrison V.A., Dale D.C., Crawford J., Delgado D.J., Fridman M. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003, 44:2069-2076.
19. Pettengell R., Bosly A., Szucs T.D., Jackisch C., Leonard R., Paridaens R., et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 2009, 144:677-685.
20. Ziepert M., Schmits R., Trumper L., Pfreundschuh M., Loeffler M. Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. Ann Oncol 2008, 19:752-762.
21. Lyman G.H., Kuderer N.M., Crawford J., et al. Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. J Clin Oncol 2006, 24(18S):8561. [ASCO Annual Meeting Proceedings Part I].
22. Moreau M., Klastersky J., Schwarzbold A., Muanza F., Georgala A., Aoun M., et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 2009, 20:513-519.
23. Cooper K.L., Madan J., Whyte S., Stevenson M.D., Akehurst R.L. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011, 11:404.
24. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 10:1011-1023.
25. Pfreundschuh M., Trumper L., Kloess M., Schmits R., Feller A.C., Rudolph C., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004, 104:626-633.
26. Pfreundschuh M., Trumper L., Kloess M., Schmits R., Feller A.C., Rübe C., et al. German High-Grade Non-Hodgkin's Lymphoma Study Group.Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.
27. Lyman G.H., Dale D.C., Friedberg J., Crawford J., Fisher R.I. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004, 22:4302-4311.